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Angiotensin II blockade decreases TGF-/31 and matrix proteins in
cyclosporine nephropathy. Angiotensin II (Ang II) is implicated in fibrosis
but the precise mechanism of this effect remains unclear. In a model of
chronic cyclosporine (C5A) nephropathy, we previously showed that
TGF-31 plays a role in CsA-induced tubulointerstitial fibrosis and arte-
riolopathy by stimulating extracellular matrix (ECM) protein synthesis
and inhibiting ECM degradation through increasing the synthesis of
plasminogen activator inhibitor (PAI)-1. We hypothesized that Ang II
contributes to fibrosis by inducing TGF-f31. Salt-depleted rats were given
placebo, CsA alone, CsA + nilvadipine, CsA + hydralazine/hydrochlor-
thiazide, CsA + losartan (AT1 receptor antagonist) or CsA + enalapril(Ang converting enzyme inhibitor) and were sacrificed at 7 and 28 days.
All treated groups achieved similar blood pressures and glomerular
filtration rates. The lesion of chronic CsA nephropathy was ameliorated by
concomitant therapy with losartan or enalapril at 28 days, a phenomenon
not observed in the other treatment groups. Similarly, Ang H blockade
resulted in decreased expression of TGF-f31 and PAT-i by Northern and
ELISA. Similarly, the expression of ECM proteins directly influenced by
TGF-ji decreased with Ang II blockade. These results suggest that
CsA-induced fibrosis in this model is independent of renal hemodynamics
and is mediated, at least partly, through Ang II induction of TGF-/31
expression.
Cyclosporine A (CsA) remains one of the most important
immunosuppressive drugs used for the management of organ
transplantation and autoimmune diseases [11. However, CsA
causes severe deleterious effects on renal structure and function,
making nephrotoxicity a major limiting side effect [2]. Chronic
CsA nephrotoxicity may progress to an irreversible renal lesion
characterized by striped interstitial fibrosis, tubular atrophy and
hyalinosis of the afferent arterioles [31. Using the observation that
sodium depletion exacerbates CsA nephrotoxicity, a reproducible
animal model of chronic CsA nephrotoxicity was established [4].
In this model, CsA treatment in rats on a low salt diet induced
physiologic and histologic features in the kidney that resemble the
human lesion described in patients on long-term CsA therapy [5].
Transforming growth factor (TGF)-pJ is a key fibrogenic
cytokine implicated in the fibrosis of a number of chronic diseases
of the kidney and other organs [6]. Our studies using the same
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model have shown that TGF-/31 is involved in the fibrosis of
chronic CsA nephropathy by increasing extracellular matrix
(ECM) deposition and decreasing its degradation [7]. Other
investigators have also shown that CsA directly stimulates the
expression of TGF-f31 in vitro in a number cell culture systems
[8, 9].
The intrarenal renin-angiotensin system (RAS) plays an impor-
tant role, not only in the regulation of glomerular hemodynamics,
but also in growth and sclerosis [10, 11]. Chronic infusion of
angiotensin II (Ang II) in rats produces interstitial fibrosis [12].
On the other hand, angiotensin converting enzyme (ACE) inhib-
itors and Ang II receptor antagonists attenuate progressive gb-
merulosclerosis and interstitial fibrosis in several disease models
and slow disease progression in several human studies [13—15].
Studies showing that glomerulosclerosis can develop and progress
in the absence of glomerular hypertension and that ACE inhibi-
tion can attenuate the progression of sclerosis without affecting
the level of glomerular pressure, raise the possibility that Ang II
may directly induce sclerosis, independent of its hemodynamic
action [161. Recently, it was reported that addition of Ang II to
cultured vascular smooth muscle cells stimulates secretion of
TGF-/3 [17]. Kagami et al have also demonstrated a link between
Ang II and TGF-p by showing that Ang II stimulation of ECM
protein synthesis in rat glomerular mesangial cells is mediated by
an increase in TGF-13 synthesis and in the conversion from latent
to active TGF-J3 [18]. In addition, Wolf et al have shown that Ang
TI-induced cellular hypertrophy is linked to TGF-f3 [19].
There is evidence to suggest that the RAS is activated in this
model of chronic CsA nephrotoxicity [20, 211. CsA administration
in salt-depleted rats causes a significant increase in juxtaglomer-
ular (JG) apparatus renin and CsA-induced interstitial fibrosis
could be prevented with the use of losartan or enalapril [201.
Others have demonstrated a beneficial effect with Ang II blockade
on CsA-induced afferent arteriolopathy, and a decrease in the
macrophage chemoattractant osteopontin [211. In patients, while
the peripheral renin activity is often normal or suppressed with
CsA treatment, there is abundant evidence of JG cell hyperplasia
within the kidney [22]. Since TGF-f3 is clearly a potent stimulator
of matrix production and deposition in chronic CsA nephropathy,
and since the renal histology of rats chronically treated with Ang
II is similar to the chronic CsA renal lesion, we hypothesized that
Ang II induces TGF-/31 production in this model and that
TGF-pl, in turn, stimulates ECM production and deposition.
Studies were initiated using losartan, an Ang II receptor AT1
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antagonist, and enalapril, an ACE inhibitor, to shed new insights
into this process. Our findings indicate that the fibrosis induced by
TGF-/31 is blunted specifically by RAS blockade with either
losartan or enalapril. The observed matrix accumulation seems to
be the result of Ang II induction of TGF-/31 leading to an increase
in matrix production and induction of plasminogen activator
inhibitor (PAI)-1 leading to a decrease in matrix degradation.
Inhibiting the RAS decreases the expression of TGF-/31 and
PAl-I with resultant decrease in the deposition of ECM compo-
nents.
METHODS
Experimental design
Animals. Adult male Sprague-Dawley rats (Charles River,
Wilmington, MA, USA), weighing 225 to 250 g, were housed in
individual cages in a temperature- and light-controlled environ-
ment, and received a low salt diet (0.05% sodium; Teklad
Premier, Madison, WI, USA), with tap water ad libitum. They
were weighed and examined daily.
Drugs. CsA (Sandimmune®), provided by Sandoz Research
Institute (East Hanover, NJ, USA), was diluted in olive oil to a
final concentration of 15 mg/mI. Vehicle (VH) consisted of an
identical volume of olive oil. Losartan (L), provided by Du Pont
Merck Pharmaceutical (Wilmington, DE, USA), was dissolved in
sterile water and orally given to animals at 10 mg/kg/day. Enalapril
(E), provided by Merck Co. (Rahway, NJ, USA), was diluted in
sterile water and orally given to animals at 10 mg/kg/day. Nilva-
dipine (N), provided by Fujisawa Pharmaceutical (Osaka, Japan),
was diluted in ethanol/olive oil and subcutaneously given to
animals at 0.5 mg/kg/day. Matrix-driven delivery pellet of hydral-
azine (H) and hydrochlorthiazide (H) (Innovative Research of
America, Toledo, OH, USA) were subcutaneously implanted in
animals and released at 10 mg/kg/day, respectively.
Experimental groups
The following experimental groups were studied:
(1.) Vehicle (WI). Rats received a daily subcutaneous injection
of olive oil, 1 mI/kg, for 7 (N = 6) and 28 days (N = 6).
(2.) CsA. Rats received a daily subcutaneous injection of CsA
15 mg/kg for 7 (N = 6) and 28 days (N = 6).
(3.) GsA + N. Rats received both a daily subcutaneous injection
of CsA 15 mg/kg and of nilvadipine 0.5 mg/kg for 7 (N = 6) and
28 days (N = 6).
(4.) CsA + HH. Rats received a daily subcutaneous injection of
CsA 15 mg/kg, and hydralazine 10 mg/kg/day and hydrochlorthia-
zide (HCTZ) 10 mg/kg/day (both by matrix-driven delivery pellet)
for 7 (N = 6) and 28 days (N = 7).
(5.) CsA + L. Rats received a daily subcutaneous injection of
CsA 15 mg/kg, and losartan 10 mg/kg by gavage for 7 (N = 6) and
28 days (N = 5). This dosage and route of administration for
losartan were selected because they have previously been shown
to significantly block Ang II receptors [231.
(6.) CsA + E. Rats received a daily subcutaneous injection of
CsA 15 mg/kg, and enalapril 10 mg/kg by gavage for 7 (N = 6) and
28 days (N = 6). This dosage and route of administration for
enalapril were selected because they have been previously shown
to significantly block ACE activity [241.
Experimental protocol
After one week on the low salt diet, weight-matched rats were
randomly assigned to the different treatment groups. At the end of
each treatment period of 7 or 28 days, tail systolic blood pressure
(BP) was measured with a plethysmograph (Natsume Seisakusyo,
Tokyo, Japan) and the rats were placed in metabolic cages (Nalge
Co., Rochester, NY, USA) for 24-hour urine collection. The urine
was collected into a plastic bag cooled with ice. Following that, the
animals were anesthetized with intraperitoneal ketamine and a
blood sample was obtained. After opening the abdomen through
a midline incision, the abdominal aorta was cannulated retro-
gradely below the renal arteries with an 18-gauge needle. With the
aorta occluded by ligation above the renal arteries and the renal
veins opened by a small incision for outflow, the kidneys were
perfused with 20 ml of cold heparinized saline. After the experi-
ment, the animals were euthanized by deep anesthesia with
ketamine, followed by exsanguination due to transection of a
major blood vessel. The left kidney was removed and was pro-
cessed for evaluation by light microscopy and immunohistochem-
istry. After removing the right kidney, the cortex was dissected
from the medulla, and the whole cortex was processed for RNA
analysis.
Functional studies
Urinary and plasma creatinine were measured by a Cobas
autoanalyzer (Roche Diagnostics, Div. Hoffman-La Roche Inc.,
Nutley, NJ, USA). The creatinine clearance (Car) was calculated
using a standard formula. To determine whole blood CsA level,
blood was collected in plastic syringes transferred to EDTA
included metal-free tubes and was stored at —20°C until deter-
mined by a monoclonal radioimmunoassay for CsA (Incstar Co.,
Stillwater, MN, USA).
Morphology
Renal tissue samples were fixed in 10% buffered formalin and
embedded in paraffin. Two to four micron thick sections were
stained with periodic acid-Schiff's reagent (PAS) and Trichrome.
Horizontal and saggital sections were both performed. The histo-
logic findings were subdivided into two categories: interstitial
inflammation and scarring, and arteriolopathy. The findings of
interstitial fibrosis consisted of matrix-rich expansion of the
interstitium with distortion and collapse of the tubules and
thickening of the tubular basement membranes. Features of
interstitial inflammation included mononuclear infiltrates, edema
and vacuolization of interstitial cells. Renal arteriolopathy was
characterized by hyalinization and destruction of the afferent
arterioles and terminal portions of interlobular arteries. A mini-
mum of 20 fields at >< 100 magnification were assessed and graded
in each biopsy by an observer masked to treatment groups using a
color image analyzer (Mustek Pentagon 800 SP; MacIntosh Power
PC 7100, NIH Image v. 1.5).
The following semiquantitative score was used to assess extent
of changes. Tubulointerstitial fibrosis was estimated by counting
the percentage of injured areas per field of cortex and medulla
and scored semiquantitatively using the following: 0 = normal
interstitium; 0.5 = < 5% of areas injured; 1 = 5 to 15% of areas
injured; 1.5 = 16 to 25% of areas injured, 2 = 26 to 35% of areas
injured; 2.5 = 36 to 45% of areas injured and 3 = > 45% of areas
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injured. Hyalinosis of the afferent arterioles was semi-quantita-
tively assessed by counting the percentage of juxtaglomerular
afferent arterioles available for examination with a minimum of
100 glomeruli per biopsy assessed: 0 = no arterioles injured; 0.5 =
< 15% of arterioles injured; I = 15 to 30% of arterioles injured;
1.5 = 31 to 45% of arterioles injured; 2 = 46 to 60% of arterioles
injured; 2.5 = 61 to 75% of arterioles injured and 3 = > 75% of
arterioles injured.
RNA analysis
Tissue from the renal cortex was finely minced with a razor
blade on ice. Total RNA was prepared by lysis in 4 M guanidine
isothiocyanate (GITC) containing 1% 2-mercaptoethanol (BME)
and 0.5% lauryl sarcosyl and ultracentrifugation of the lysate on a
cesium chloride cushion. After resuspension in Tris-EDTA buffer,
RNA concentrations were determined using spectrophotometric
readings at Absorbance2c,o. Thirty micrograms of RNA were
electrophoresed in each lane in 0.9% agarose gels containing 2.2
M formaldehyde and 0.2 M Mops (pH 7.0) and transferred to a
nylon membrane (ICN Biomedicals, Inc., Costa Mesa, CA, USA)
overnight by capillary blotting. Nucleic acids were crosslinked by
ultraviolet irradiation (Stratagene, La Jolla, CA, USA). The
membranes were prehybridized for two hours at 42°C with 50%
formamide, 10% Denhardt's solution, 0.1% SDS, 5x standard
saline citrate (SSC), and 200 pg/ml denatured salmon sperm
DNA. They were then hybridized at 42°C for 18 hours with eDNA
probes labeled with 32P-dCTP by random oligonucleotide priming
(Boehringer Mannheim Corp., Indianapolis, IN, USA). The blots
were washed in 2 >< SSC, 0.1% SDS at room temperature for 15
minutes and in 0.1 x SSC, 0.1% SDS at 50°C for 15 minutes.
Films were exposed at —70°C for different time periods to ensure
linearity of densitometric values and exposure time. Autoradio-
graphs were scanned on a laser densitometer (Ultrascan XL;
Pharmacia LKB Biotechnology, Inc.). The density of hands for the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
was used to control for differences in the total amount of RNA
loaded onto each gel line. For quantitative purposes, the values
were divided by the density of bands for GAPDH in the same
lane. The following probes were used for Northern blot analysis.
A mouse TGF-f31 eDNA probe (plasmid MUI5) was kindly
provided by R. Derynck [25]. A rat PAl-i eDNA probe [plasmid
pBluescript SK(—)] was obtained from T.D. Gelehrter [261.
Plasmid P16, which contains a human biglycan insert, was a kind
gift of L.W. Fisher [27]. A rat procollagen u1 eDNA (plasmid
palRl) was obtained from D. Rowe [28]. A rat collagen IV eDNA
probe (plasmid pCIV-1-PEJ6) was purchased from American
Type Culture Collection (Rockville, MD, USA) [29]. A rat
GAPDH eDNA probe (plasmid pBluescript KS II) was a gener-
ous gift from J.M. Blanchard F30].
immunohistochemistry
lmmunofluorescence microscopy was performed on tissues
snap frozen in cold isopentane with a cryostat microtome (Miles
Scientific, Naperville, IL, USA) as previously described [7, 311.
Four micrometer cryostat sections were fixed in acetone and
washed in PBS, pH 7.4. The deposition of the ECM components
tenascin and fIbroneclin-cellu!ar containing extra domain A (fi-
bronectin EDA+) was determined. The primary antibodies used
were rabbit anti-human tenascin (Life Technologies, Gaithers-
burg, MD, USA) and mouse anti-human fibronectin EDA+
(Sera-lab, Crowley Down, UK). The secondary antibodies used
were fluorescein isothiocyanate (FITC)-conjugated F(ab')2 don-
key anti-rabbit IgG (Jackson Immunoresearch, West Grove, PA,
USA) and FITC-conjugated F(ab')2 rat anti-mouse IgG (Jackson
Immunoresearch). A minimum of 20 randomly selected areas per
sample were observed at x250 magnification. The intensity of
staining for the glomerular, tubulointerstitial and vascular com-
partments was evaluated by an observer blinded to the treatment
groups using the following semiquantitative scale: U = diffuse,
very weak or absent staining, 1 = staining involving less than 25%,
2 = staining involving 25% to 50%, 3 = staining involving 50% to
75% and 4 = staining involving 75% to 100%. Photographs were
obtained at identical exposure and development time intervals.
Immunoassay
Frozen (—70°C) kidney tissue sections embedded in Tissue-Tek
O.C.T. compound (Miles Inc. Diagnostics Div., Elkhart, IN, USA)
were processed for protein extraction. Tissue was thawed at 4°C in
5 ml lysis buffer (GITC/BME) then rinsed x3 in 5 ml cold 4°C
PBS pH 7.4. Protein extracts were prepared by homogenizing
kidney tissue in I ml cold PBS containing 0.05% Tween 20
(PBS-T) with a glass tissue homogenizer (Kontes Glass, Vineland,
NJ, USA). The homogenate was centrifuged at 4°C for 15 minutes
at 15,000 Xg and the supernatant was collected then centrifuged
to remove cellular debris. Protein concentration in the superna-
tant was determined using the Micro BCA (bicinchoninic acid)
assay (Pierce, Rockford, IL, USA).
TGF-pl protein in the supernatant was quantified using a
commercial enzyme-linked immunosorbent assay (ELISA) kit
(R&D Systems, Minneapolis, MN, USA). The absorbance of the
colored reaction product was read at 450 and 546 nm wavelengths
using an automated microtiter plate reader (Molecular Devices,
Menlo Park, CA, USA).
To determine PAl-I, an inhibitory ELISA technique modified
from the method of Rennard et al [32] was used. Wells in a
microtiter plate were coated with rat PAI-l antiserum (American
Diagnostics, Greenwich, CT, USA). To another plate, serial
dilutions of standard or unknown samples and rabbit IgG anti-
PAl-I (American Diagnostics) were added. After washing the
coated plate, aliquots of the second plate were added to the
coated plate and incubated. After washing, horseradish peroxi-
dase-conjugated goat anti-rabbit IgG (Pierce) was added and
developed using standard methods. Absorbance (450 nm) was
read using a microtiter plate reader (Molecular Devices).
Statistical analysis
Results are presented as mean standard error. Comparisons
between the CsA group and the other experimental groups were
done by Kruskal-Wallis test followed by Turkey test. The level of
statistical significance was chosen as P < 0.05.
RESULTS
Physiologic studies
Although weight gain was progressive in all experimental
groups, animals treated with CsA failed to gain as much weight as
those receiving VH with the difference achieving statistical signif-
icance (P < 0.01) at day 28. however, the final body wt of' all
CsA-treated rats (regardless of their treatment with nilvadipine,
hydralazine-HCTZ, losartan or enalapril) was similar (data not
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Table 1. Changes in CsA whole blood level, systolic blood pressure, serum creatinine, and creatinine clearance (GFR) in the different
experimental groups at 7 and 28 days
CsA whole blood level
ng/ml
7 days 28 days
Systolic bI
m
ood pressure
m Hg
Serum creatinine
mg/dl_____
GFR
ml/min/100 g
7 days 28 days 7 days 28 days 7 days 28 days
VH 0 0 0 0 152 2 143 2 0.59 0.04 0.57 0.02 0.36 0.01 0.39 0.02'
CsA 2752 136 5164 270 149 8 144 4 0.63 0.02 1.02 0.06 0.30 0.01 0.20 0.01
CsA + N 2693 204 5256 309 122 2 125 5' 0.65 0.07 1.06 0.07 0.27 0.05 0.22 0.02
CsA + HH 2425 282 4295 293 106 6h 98 6b 0.72 0.06 1.14 0.06 0.32 0.03 0.18 0.01
CsA + L 3391 326 4374 688 98 45 93 4' 1.45 0.16° 2.37 0.41° 0.15 0.02° 0.09 0.01°
CsA + E 2819 351 4488 658 108 6 90 5 ill 0.20' 1.85 0.16' 0.19 0.04° 0.11 0.0l'
Mean SCM of 5 to 7 rats
Abbreviations are: VH, placebo; CsA, cyclosporine; N, nilvadipine; HH, hydralazine and hydrochlorthiazide; L, losartan; E, enalapril.
°P <0.05 vs. CsA
P < 0.01 vs. CsA
shown). There was a progressive increase in CsA whole blood
level in all CsA-treated groups. However, all animals receiving
CsA achieved similar CsA whole blood levels (Table 1).
CsA-induced hypertension was not observed in this model. On
the other hand, the addition of losartan or enalapril caused art
early, sustained, and significant decrease in systolic blood pressure
at both 7 (P < 0.01) and 28 days (P < 0.01) when compared to the
CsA only-treated group (Table 1). To assess the role of blood
pressure decrease in the observed amelioration of CsA-induced
interstitial fibrosis, four groups of rats were randomized to receive
nilvadipine for 7 and 28 days or a combination of hydralazine and
HCTZ for 7 and 28 days. This combination of drugs reduced the
blood pressure to the same extent as in the CsA + losartan and
CsA + enalapril groups, respectively (Table 1).
Renal function data for the different treatment groups are
summarized in Table 1. All CsA-treated animals had a significant
increase in serum creatinine by day 28 (P < 0.01) when compared
to the VH-treated group. In addition, all CsA-treated rats expe-
rienced a decline in glomerular filtration rate (GFR) as measured
by creatinine clearance that was present by day 7 but became
more significant at 28 days (P < 0.01). Animals treated with CsA
+ nilvadipine or CsA + hydralazine and HCTZ had a significantly
higher GFR compared to those treated with CsA + losartan or
CsA + enalapril (P < 0.01). However, there were no significant
differences in GFR between the CsA only, GsA + nilvadipine and
CsA + hydralazine-HCTZ groups (Table 1).
Histologic changes
Rats treated with CsA only had characteristic morphologic
findings that were mostly evident at 28 days and were similar to
the chronic human CsA renal lesion. There was a mononuclear
cellular infiltrate and early tubular injury by day 7. Rats treated
with CsA only developed a striped interstitial fibrosis with pro-
gressive inflammatory cell infiltrates associated with thickening of
the tubular basement membranes (TBM) and Bowman's capsule
(Fig. IA). There was focal disruption of the TBM in some areas of
interstitial infiltrate with loss of tubular definition. When the
extent of changes in interstitial fibrosis was graded using a 0 to 3 +
semiquantitative score, most differences were observed at 28 days
(Table 2). The concurrent administration of losartan or enalapril
with CsA dramatically decreased interstitial fibrosis (P < 0.01)
and to the same extent (Fig. IB) when compared to the CsA
only-treated group. On the other hand, CsA-induced interstitial
fibrosis was not affected by the concurrent use of nilvadipine and
was worsened by the hydralazine-HCTZ combination (Table 2).
The vascular lesion in CsA only-treated rats was characterized
by arteriolar hyalinosis consisting of hyalin deposition within the
tunica media of afferent arterioles and the terminal portions of
the interlobular arteries (Fig. 1C). In comparison to the CsA
only-treated group, his arteriolopathy was significantly attenuated
by losartan (P < 0.01) and enalapril (P < 0.01) (Fig. 1D). On the
other hand, the use of nilvadipine or hydralazine-HCTZ was
without effect on the arteriolopathy (Table 2). The beneficial
effect of Ang II blockade was more significant in preventing
CsA-induced arteriolopathy (P < 0.01) than interstitial fibrosis
(P < 0.05).
Expression of TGF-pl and PAt-i mRNA
Northern blot analysis. TGF-J31 mRNA was progressively in-
creased by day 7 (P < 0.05) and more so at day 28 (P < 0.001) in
the CsA only-treated rats when compared to VH rats. The
decrease in TGF-131 mRNA expression in the rats treated with
nilvadipine, hydralazine-HCTZ, losartan or enalapril was not seen
until 28 days. Losartan dramatically decreased TGF-pl mRNA
expression (P < 0.01) by 60% when compared to the CsA only
group. The amelioration in TGF-13l mRNA expression seen with
enalapril was not as impressive (40%) but was still significant (P <
0.05). In addition, nilvadipine ameliorated TGF-/31 mRNA ex-
pression by 30% (P < 0.05) while the combination of hydralazine-
HCTZ had no effect on TGF-pl mRNA expression (Figs. 2 and
3A).
The mRNA expression of PAL-i, a protease inhibitor that
blocks ECM degradation and is directly stimulated by TGF-, is
shown in Figures 2 and 4A. PAl-i mRNA, in parallel to TGF-pl
mRNA expression, was up-regulated in the CsA only-treated
groups at 28 days (P < 0.001). Similar to TGF-pl expression, the
change in PAT-I mRNA expression in the groups treated with
nilvadipine, hydralazinc-HCTZ, losartan or enalapril was not
observed until 28 days. Both losartan and enalapril decreased
PAl-I mRNA expression to the same extent (P < 0.01) when
compared to the CsA only group, an effect not seen this time with
the nilvadipine group. On the other hand, treatment with hydral-
azine-HCTZ resulted in an increase in PAT-i mRNA expression
when compared to the CsA only group.
Immunoassay. To assess whether the changes in mRNA expres-
sion were translated into a change in the synthesis of TGF-J31 and
S.
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Fig. 1. Effect of losartan on CsA-induced chronic nephropathy. Micrographs showing the renal cortex of salt-depleted rats given CsA 15 mg/kg/day (A,
C) or a combination of CsA 15 mg/kg/day and losartan 10 mg/kg/day (B, D) for four weeks. Extensive interstitial fibrosis and tubular atrophy along a
medullary ray are seen in a CsA only-treated animal (A, Trichrome x200). These changes arc markedly reduced with concurrent use of losartan (B,
Trichrome ><200). Also shown in a CsA only-treated rat is the characteristic degenerative lesion of the afferent glomerular arteriole with accumulation
of eosinophilic material (C, PAS x200). These changes were markedly ameliorated with the use of losartan (D, PAS X200).
Tubulointerstitial
fibrosis Arteriolopathy
7 days 28 days7 days 28 days
VH 0±0 00h 0.1±0.1
CsA 0 0 1.5 i 0.3 0.1 0.1
CsA + N (1 0 1.3 0.3 0.1 0.1
CsA + HH 0.1 0.1 2.1 0.2 0.1 0.1
CsA + L 0 0 0.7 0.1 0.1 0.1
CsA + F. 0 0 0.8 0.2 0.1 0.1
Mean SCM of 5—7 rats
Abbreviations are: VH, placebo; CsA, cyclosporine; N, nilvadipine; HH,
hydralazine and hydrochlorthiazide; L, losartan; E, enalapril.
P < 0.05 vs. CsA
5p <0.01 vs. CsA
PAT-i proteins, ELISA was performed on tissue homogenates.
The expression of TGF-pl protein was similar to its mRNA
expression (Fig. 3B) in all the experimental groups. It increased at
day 7 (P < 0.001) and more so at day 28 (P < 0.001) in the CsA
only-treated rats when compared to VH rats. There was a
decrease in TGF-f31 expression in the rats treated with nilvadip-
me, hydralazine-HCTZ, losartan or enalapril at seven days.
However, this effect was not sustained at 28 days except in the
losartan and enalapril groups. Losartan dramatically decreased
TGF-pI protein expression (P < 0.01) when compared to the CsA
only group. The amelioration in TGF-f31 expression seen with
enalapril was not as impressive but was still significant (P < 0.01).
In addition, nilvadipine ameliorated TGF-/31 expression but the
results were not statistically significant, while the combination of
hydralazine-I1CTZ had no effect on TGF-131 expression.
The expression of PAl-I by ELISA is shown in Figure 4B.
PAl-I expression was similar to its mRNA expression and was
up-regulated in the CsA only-treated groups at 7 (P < 0.01) and
28 days (P < 0.001). The change in PAl-I protein expression in
the groups treated with nilvadipine, hydralazine-HCTZ, losartan
or enalapril was not observed until 28 days. Both losartan and
enalapril decreased PAl-i expression to the same extent (P <
0.01) when compared to the CsA only group, an effect not seen
with the hydralazine-l-ICTZ group. Treatment with nilvadipine
resulted in some amelioration in PAl-i expression, although not
to the same extent.
Extracellular matrix deposition in the kidney
Northern blot analysis. The proteoglycan biglycan is a compo-
nent of the ECM directly stimulated by TGF-/3. The mRNA
Table 2. Semi-quantitative scoring by light microscopy of the extent of
changes observed in the different experimental groups for
tubulointerstitial fibrosis and arteriolopathy
0.2 0.1"
1.8 0.2
1.7 0.2
2.1 0.1
0.3 0.1"
0.3 0.1"
—
a
 :.
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TGF-31
PAl- 1
Biglycan
Collagen I
Collagen IV
GAPDH
I
-J z w I
+ + + +
< < < <I ci) (I) (1) Ci) (I)
> 0 0 0 0 0
Fig. 2. Northern blotting of mRNA from the cortex of salt-depleted rat
kidneys. Representative gel of total RNA isolated from whole cortex at 28
days from rats treated with placebo (VH), CsA only 15 mg/kg/day, CsA +
nilvadipine (CsA + N), C.sA + hydralazine/HCTZ (CsA + HH), CsA +
losartan (CsA + L), and CsA + enalapril (CsA + F). RNA was hybridized
with eDNA probes to TGF-frl, PAl-I, biglycan, type I collagen, and
GAPDH. Molecular size markers are shown on the right.
expression of biglycan was similar to TGF-/31 and was progres-
sively elevated in the CsA only-treated group compared to the VH
group (P < 0.01 at day 7 and P < 0.001 at day 28), suggesting
active matrix synthesis. Concomitant treatment with nilvadipine,
hydralazine-HCTZ, losartan or enalapril did not produce any
change in the mRNA expression of biglycan until day 28. Both
losartan and enalapril dramatically decreased biglycan mRNA
expression (P < 0.001) relative to the CsA only group, although
the changes were more significant with the losartan group. While
the use of nilvadipine and hydralazine-HCTZ ameliorated bigly-
can mRNA expression relative to the CsA only group (P < 0.01),
the changes seen with Ang II blockade were more significant
(Figs. 2 and 5).
Collagen type I is normally present in the interstitial component
of the kidney and its expression is increased in pathological
conditions under the direct influence of TGF-13. In the CsA
only-treated group, the mRNA expression of type I collagen was
similar to TGF-pl and PAl-i mRNA expression and was up-
regulated throughout the study period (P < 0.01) relative to the
VH group. Concomitant treatment with losartan (P < 0.05) or
enalapril resulted in a decrease in mRNA expression of type I
collagen relative to the CsA only group as early as day 7, although
more significant changes were seen at day 28 (P < 0.01). While no
difference in type I collagen mRNA expression was observed with
nilvadipine, the early improvement seen with hydralazine-HCTZ
Kb at day 7 (P < 0.05) was lost by day 28 (Figs. 2 and 6).
On the other hand, the mRNA expression of type IV collagen,
— 2 5 a component of glomerular and tubular basement membranes,
was different and is shown in Figures 2 and 7. While CsA
treatment increased type IV collagen mRNA expression as com-
pared to the VH group, there was no difference with concomi-
— 3 1 tantly therapy with nilvadipine, hydralazine-HCTZ, losartan or
enalapril. In other words, the beneficial effect of treatment with
losartan or enalapril observed in the mRNA expression of bigly-
can and type I collagen was specific and was not observed with
type IV collagen.
— 2.6 Immunohistochemisriy. To assess whether the change in mRNA
expression was translated into a change in the synthesis and
deposition of matrix proteins, certain components of the ECM
—
were identified by immunofluorescence. This allowed us to deter-
mine which kidney compartments (glomeruli, tubulointerstitium
— orvessels) were most extensively involved in matrix expansion and
to identify the site of the most beneficial effect of Ang II blockade.
We examined the expression of the glycoproteins tenascin and
fibronectin EDA+. The amount of tenascin and fibronectin
— 6 5 EDA+ was elevated in the kidneys of CsA only-treated rats as
compared to VH at both days 7 and 28 in the glomeruli,
tubulointerstitium and vessels (Figs. 8 and 9). Most of the increase
in the expression of tenascin and fibronectin EDA+ in CsA
only-treated kidneys was observed in the tuhulointerstitium and
— 1 .3 vessels (P < 0.01), a finding in agreement with the characteristic
histology of chronic CsA nephrotoxicity (Fig. 9).
Treatment with the combination of hydralazine and HCTZ did
not decrease the expression of tenascin or fibronectin EDA+ in
the glomeruli, tubulointerstitium or vessels (Fig. 9). In addition,
treatment with nilvadipine was, for the most part, not effective
except for a mild amelioration in the glomerular expression of
fibronectin EDA+ at 28 days (P < 0.05) and in the tubulointer-
stitial expression of tenascin at 28 days (P < 0.05) (Fig. 9).
However, the most impressive changes were observed in the
kidneys of rats treated with losartan or enalapril, with a greater
degree of significance reached in the losartan-treated kidneys
(Figs. 8 and 9). The beneficial effect with Ang II blockade was
achieved at 28 days and was observed to a greater degree in the
tubulointerstitium and vessels. The use of losartan decreased the
expression of tenascin (P < 0.01) and fibronectin EDA+ (P <
0.001) in the tubulointerstitium and vessels (P < 0.01 for both) at
28 days. The changes were also observed in the glomeruli (P <
0.01), although to a lesser extent. Despite being less significant
than with losartan, enalapril resulted in a similar beneficial effect
on the expression of tenascin (P < 0.05) and fibronectin EDA+
(P < 0.01) at 28 days (Figs. 8 and 9).
DISCUSSION
We have previously shown an elevated expression of TGF-pI,
PAl-I and certain matrix components in this model of chronic
CsA nephrotoxicity [7]. We then proposed that TGF-131 is in-
volved in CsA-induced renal fibrosis by directly increasing matrix
deposition and by decreasing matrix degradation through increas-
ing PAl-i expression. We also demonstrated recently that a
similar mechanism of increased matrix production and decreased
A
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Fig. 3. Quantitation of cortical mRNA
expression of TGF-J31 in salt-depleted rat
kidneys relative to GAPDH. (A) Total RNA
was isolated from whole cortex at days 7 and 28
and was hybridized with a eDNA probe to
TGF-f31. (B) TGF-j31 protein expression was
determined by ELISA from whole cortex
homogenates. Abbreviations are: VH, placebo;
CsA, cyclosporine; N, nilvadipine; HH,
hydralazine and hydrochlorthiazide; L, losartan;
E, enalapril. N = 5 to 7 for each group. *p <
0.05, < 0.0t and *** < 0.001 compared
to CsA only-treated group.
degradation under the influence of TGF-J31 leads to matrix
accumulation in experimental and human chronic rejection [31,
331. In addition, TGF-p has been clearly shown to have potent
immunosuppressive activities [34]. As a result, it was proposed
that the immunosuppression and renal fibrosis associated with
CsA can all he mediated, at least partly, by TGF-(3 [35] and thus,
may contribute to the fibrotic lesion of "chronic allograft failure."
Ang IT has been implicated in pathological matrix accumulation
in several different animal models of progressive glomeruloscie-
rosis and interstitial fibrosis and in patients with chronic renal
diseases [10—12]. En addition, Ang II was shown to participate in
other tissues in the fibrotic response [36—391. On the other hand,
ACE inhibitors and AT1 receptor antagonists have both been
shown to attenuate or even reverse fibrosis in a number of animal
and human diseases of the kidney [13—15] and other organs
[40—43]. Since the RAS has been shown to be activated in this
model, our hypothesis was that CsA increases Ang II which then
has a direct effect on TGF-131 production. This hypothesis is
consistent with recent data showing that Ang II stimulates the
expression of TGF-1 in vascular smooth muscle and mesangial
cell cultures [17—19]. We further hypothesized that the TGF-pi
produced in response to Ang 11 treatment stimulates the produc-
tion of matrix components which then lead to pathological matrix
accumulation. We evaluated the matrix components biglycan, type
I collagen, tenascin and fibronectin which are known to be
increased by TGF-p and which are associated with the process of
fibrosis [44—47]. The data presented here support our hypothesis.
In this paper, we show that CsA-induced interstitial fibrosis and
arteriolopathy are blunted specifically by blocking the RAS with
either losartan, an AT1 receptor antagonist, or enalapril, an ACE
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Fig. 4. Quantitation of cortical mRNA
expression of PA!-! in salt-depleted rat kidneys
relative to GAPDH. Total RNA was isolated
from whole cortex at days 7 and 28 and was
hybridized with a cDNA probe to PAT-I. PAT-i
protein expression was determined by ELISA
from whole cortex homogenates. Abbreviations
are in Fig. 3 legend. N = 5 to 7 for each group.
**p < 0.01 and *** < 0.001 compared to CsA
only-treated group.
inhibitor. Inhibiting the RAS decreased the expression of TGF-f31
with a resultant decrease in the accumulation of matrix compo-
nents suggesting a role for Ang II in the up-regulation of TGF-131
and resultant matrix deposition in this model. This effect seems to
be very specific since the expression of type IV collagen, an ECM
protein preferentially present in basement membranes, is not
influenced by RAS blockade.
Au increased plasma renin activity (PRA) and tissue renin
expression have been clearly demonstrated in this animal model
of chronic CsA nephropathy [20, 21]. Feeding rats a low-salt diet
has been previously shown to increase PRA, renal renin mRNA,
and renal and plasma Ang II and ACE [48, 49]. On the other
hand, CsA-treated rats placed on a normal-salt diet fail to develop
the disease [5]. However, while CsA treatment in rats consistently
up-regulates the RAS [20, 21, 50], the results in human are
somewhat conflicting. Human subjects treated with CsA demon-
strate an unchanged or even a slight decrease in PRA but have
evidence of JG cell hyperplasia [51, 52]. On the other hand,
plasma prorenin and renin concentrations have been shown to he
increased in CsA-treated heart and liver allograft recipients [53].
In addition, conversion from CsA to azathioprine in renal trans-
plant recipients led to a decrease in renal renin-containing cells
[541.
Since one possible explanation for the observed protection with
the use of losartan or enalapril could be related to the ameliora-
tion of ischemia produced by CsA-associated arteriolar vasocon-
strictiori, GFR was measured in all the treatment groups. In sharp
contrast to what was expected, there was worsening of the GFR in
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Fig. 5. Quantitation of cortical mRNA expression of biglycan in salt-
depleted rat kidneys relative to GAPDH. Total RNA was isolated from
whole cortex at days 7 and 28 and was hybridized with a eDNA probe to
biglycan. Abbreviations are in the legend of Fig. 3. < 0.01 and *** <
0.001 compared to CsA only-treated group.
Fig. 6. Quantitation of cortical mRNA expression of type I collagen in
salt-depleted rat kidneys relative to GAPDH. Total RNA was isolated
from whole cortex at days 7 and 28 and was hybridized with a eDNA probe
to type I collagen. Abbreviations are in the legend of Fig. 3. N = 5 to 7 for
each group. *p < 0.05 and < 0.01 compared to CsA only-treated
group.
the losartan and enalapril-trealed animals. This is Consistent with
previous observations in this model [20]. This discrepancy may be
the result of not only efferent vasodilation as a result of RAS
blockade but may also be related to a low systemic blood pressure.
Since afferent arterioles are less able to autoregulate when
exposed to CsA [55], significant hypotension may compromise
glomerular perfusion pressure. As a result, although vasodilation
would have been a logical explanation for the prevention of
interstitial fibrosis and arteriolopathy, it is unlikely to he seen
when the GFR is reduced. In addition, the protective effect of
RAS blockade cannot be related solely to blood pressure reduc-
tion because a comparable decrease of the blood pressure with
Fig. 7. Quantitation of cortical mRNA expression of type IV collagen in
salt-depleted rat kidneys relative to GAPDH. Total RNA was isolated
from whole cortex at days 7 and 28 and was hybridized with a eDNA probe
to type IV collagen. Abbreviations are in the legend of Fig. 3. N = 5 to 7
for each group. ***p < 0.00 1 compared to CsA only-treated group.
nilvadipine or with the combination hydralazine and HCTZ failed
to protect the animals. On the other hand, the decrease in GFR
may explain some of the beneficial effect observed with Ang II
blockade because the associated decrease in tubular workload
may alleviate tissue hypoxia independently from its effect on
oxygen supply. In another rat model of CsA nephropathy, felo-
dipine, a dihydropyridine calcium channel blocker was capable of
reducing functional CsA nephrotoxicity but did not prevent the
interstitial damage [561. In addition, while administration of an
antagonist to endothelin A/B receptors in salt-depleted rats
ameliorated GFR, it did not protect from structural damage
associated with CsA [571. By contrast, tubulointerstitial fibrosis
was less in enalapril-treated rats despite a lack of functional
protection [57]. Our results are also consistent with previous
studies where CsA-treated rats were administered a different
antihypertensive regimen to decrease blood pressure similarly.
Again, only enalapril or losartan limited CsA-induced renal
fibrosis [20, 58]. These data, in addition to our observations,
suggest that the protective effect of RAS blockade can be disso-
ciated from renal hemodynamic effects.
The most striking histological injuries in this model have been
shown to occur in the inner stripe of the outer medulla and in the
medullary rays which have limited oxygen availability, and are
thus particularly vulnerable to ischemia [4]. Consistent with this
observation, we have also previously shown that the expression of
TGF-131 and different ECM components was most significant in
the medulla of salt-depleted rats administered CsA [7], Interest-
ingly, both rat and human kidneys show a high concentration of
AT1 receptors in the inner zone of the Outer medulla suggesting
that regional regulation of medullary blood flow is influenced by
Ang [1 [591. These ATI receptors are thought to he largely
occupied by locally produced Ang II and may play a role in the
development of the lesion of chronic CsA nephropathy [60]. Thus,
another explanation for the relative protection observed in rats
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Fig. 8. Representative immunofluorescence micrographs in salt.depleted rat kidneys. Kidney Sections from rats treated for 28 days with VH 14, E),
CsA 15 mg/kg/day alone (B, F), CsA and losartan (C, G) and CsA and enalapril (D, H) were stained with an antibody to tenascin (A to D) and fibronectin
EDA+ (E to f-I). The photographs were taken under identical conditions with equal exposures of 60 seconds (magnification X250).
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Fig. 9. Quantitation of deposition of the
glycoproteins tenascin and fibronectin EDA+
in salt-depleted rat kidneys. (A) Glomerular
staining, (B) tubulointerstitial staining, and (C)
vessels staining scores at days 7 and 28.
Symbols are: (LII) placebo; () cyclosporine; (El)
nilvadipine; () hydralazine and
hydrochlorthiazide; (I) losartan; (El) enalapril.N = 5 to 7 for each group, *p < 0.05, P <
0.01 and *** < 0.001 compared to CsA only-
treated group.
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treated with losartan or enalapril could be related to a preserva-
tion of medullary flow that would have been otherwise compro-
mised by activation of the RAS.
One important pathogenic mechanism relates to a direct stim-
ulation of TGF-31 by Ang 11117—191. Separate from its effects on
blood pressure and tissue injury, Ang II contributes to the
excessive repair that characterizes fibrosis by inducing TGF-,
which then induces matrix synthesis. This hypothesis was substan-
tiated in our data where losartan, an AT1 receptor antagonist, and
enalapril, an ACE inhibitor, separately decreased TGF-pl expres-
sion, which resulted in a decreased expression of different matrix
components and of PAl-I, an inhibitor of matrix degradation.
Along those lines, Ang 11 blockade has also been shown to
decrease TGF- expression in the setting of spontaneously hyper-
tensive rats, obstructive nephropathy and immune complex ne-
phritis 161—651. However, the reduction in TGF-f3 expression in
those studies was never absolute, suggesting that other Ang
11-independent mechanisms may be operating in regulating
TGF-p expression. In our study, the decrease in TGF-1 expres-
sion was approximately 60% with losartan and 40% with enalapril.
The decrease in the expression of the various matrix components
was similar to that of TGF-pl, further suggesting that the
apparent amelioration in fibrosis in this model was related to a
specific Ang Il-mediated effect on TGF-pl.
In addition to its effect on matrix synthesis, recent reports have
suggested that Ang II up-regulates PAl-I in cultured brain
astrocytes, vascular endothelial cells and vascular smooth muscle
cells [66—68]. PAl-i inhibits the plasminogen activators u-PA and
t-PA that convert plasminogen by plasmin, and is thus fibrogenic
by decreasing matrix degradation [69]. In this study, the use of
losartan or enalapril led to a decrease in PAl-i expression. Thus,
an additional beneficial effect seen with blockade of the RAS may
be related to an independent effect of Ang 11 on PAl-I expression
leading to a decrease in matrix degradation. Since TGF-131 can
directly stimulate PAl-I [47], the decrease in PAl-I expression
with RAS blockade could he either a direct effect of Ang 11 on
PAl-i synthesis or an indirect one by decreasing Ang Il-mediated
TGF-pl expression.
In summary, our data are consistent with a role for Ang
Il-induced and TGF-131 -mediated alterations in ECM production
and deposition in chronic CsA nephropathy. Blockade of the RAS
with an Ang 11 receptor antagonist or an ACE inhibitor strikingly
prevented the interstitial fibrosis and arteriolopathy characteristic
of chronic CsA nephropathy. The long-term consequences of the
decrease in GFR observed with ANG II blockade in this model
will still need to be investigated. In the future, therapeutic
interventions aimed at blocking the RAS in patients on long-term
CsA may help ameliorate or prevent chronic CsA nephropathy
and may lead to prolongation of graft survival. However, it is
unclear from this study whether blocking the RAS is needed at the
same time CsA treatment is initiated or whether it can still he
effective after CsA has been administered for a variable amount of
time. Future studies will help to elucidate this important question.
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